# Tirzepatide Weight Loss: The Trial Evidence > Tirzepatide weight loss outcomes from the SURMOUNT trials — what percentage of body weight was lost, how fat versus lean mass split, and what the 2025 head-to-head data showed against a comparator. ## The short version Tirzepatide weight loss outcomes in clinical trials are among the largest measured in randomised placebo-controlled studies for any approved pharmacological agent. In SURMOUNT-1 (n=2,539, 72 weeks, adults with obesity and without diabetes), mean body weight change reached -20.9% at the highest studied dose versus -3.1% with placebo [4]. In the 2025 head-to-head SURMOUNT-5 (n=751), tirzepatide produced -20.2% versus -13.7% body weight change with the comparator over the same 72-week period [5]. These are measured, cited figures from peer-reviewed randomised trials in the New England Journal of Medicine. This page walks through what those numbers mean, how fat versus lean mass split, and what the evidence shows about maintaining and losing weight over time. ## Tirzepatide results: the SURMOUNT-1 and SURMOUNT-5 numbers **SURMOUNT-1** (Jastreboff AM et al., N Engl J Med 2022): In 2,539 adults with obesity (body mass index, or BMI, >=30, or >=27 with a weight-related health condition) and without type 2 diabetes, once-weekly tirzepatide was given in three doses (5, 10, and 15 mg) for 72 weeks using a stepwise titration over the first 20 weeks. The tirzepatide weight loss measured at 72 weeks: - 5 mg: -15.0% mean body weight change (versus -3.1% with placebo) - 10 mg: -19.5% - 15 mg: -20.9% Gastrointestinal events were the most common side effects, occurring primarily during dose escalation. The trial also found that tirzepatide substantially increased the proportion of participants achieving >=10%, >=15%, >=20%, and >=25% weight reduction versus placebo [4]. **SURMOUNT-5** (Aronne LJ et al., N Engl J Med 2025): In 751 adults with obesity and without type 2 diabetes, participants were randomised to the maximum tolerated dose of tirzepatide (10 or 15 mg) or the maximum tolerated dose of a comparator (a once-weekly subcutaneous injectable approved for the same indication) for 72 weeks. The primary endpoint — least-squares mean body weight change at 72 weeks — was -20.2% with tirzepatide versus -13.7% with the comparator (P<0.001). Tirzepatide also produced a greater reduction in waist circumference and higher proportions of participants reaching every weight-reduction threshold from 10% to 25% [5]. An extended follow-up analysis from the SURMOUNT-1 programme (Jastreboff AM et al., N Engl J Med 2025) also assessed tirzepatide's effects on diabetes prevention in adults with obesity and prediabetes, finding sustained weight reduction and reduced progression to type 2 diabetes [28]. ## How does tirzepatide work for weight loss? Tirzepatide works for weight loss through its dual activation of the GIP and GLP-1 receptors, which produces several converging effects on energy intake and energy expenditure. GLP-1 receptor agonism in the brain and gut suppresses appetite and slows gastric emptying — this reduces the rate at which food moves from the stomach to the intestine, prolonging the feeling of fullness. GIP receptor agonism in the brain and adipose tissue (body-fat tissue) adds further satiety signalling and appears to increase energy expenditure. Together, these pathways produce what patients frequently describe as a 'quieting' of food-related thoughts — a reduction in appetite that goes beyond simple caloric restriction [1] [27]. A 2025 Annual Review mechanistic synthesis showed how the GIP receptor pathway in the brain and the hepatic/adipose glucagon receptor pathway synergise with GLP-1R agonism to curb feeding and increase caloric combustion [27]. Importantly, the weight lost is not purely fat. A SURMOUNT-1 DXA substudy (Look M et al., Diabetes Obes Metab 2025, n=160) measured body composition directly using dual-energy X-ray absorptiometry. Of the total weight lost at 72 weeks, approximately 75% was fat mass and approximately 25% was lean mass (muscle and other non-fat tissue) — a proportion consistent across most subgroups studied [10]. A broader systematic review across incretin trials put the median muscle-attributable share of weight loss near 28% [15]. ## Does tirzepatide burn fat or just suppress appetite? The mechanism review and the body-composition data together answer this question. Tirzepatide produces its weight-loss effect through both reduced energy intake (appetite suppression) and, the evidence suggests, some increase in energy expenditure — not purely by suppressing appetite alone. Mechanistic studies have found GIP receptor activation in adipose tissue and the brain contributes signals that are distinct from GLP-1 receptor agonism, and that engaging both pathways in the same molecule produces larger weight losses than a selective GLP-1 agonist alone, as measured in head-to-head trials [3] [5]. The SURMOUNT-1 post hoc analysis also found weight loss was not solely attributable to gastrointestinal adverse events — participants who experienced GI symptoms and those who did not lost comparable amounts of weight, indicating the appetite-suppression and metabolic mechanisms operate independently of the GI side-effect profile [35]. A post hoc SURMOUNT-1 analysis (Linetzky B et al., Ann Intern Med 2025, n=1,605) mapped tirzepatide results in cardiometabolic markers against degree of weight loss: blood pressure, insulin resistance (HOMA-IR), and HbA1c improved even with modest weight loss (steepest effects between <5% and <20% reduction), while improvements in triglycerides, HDL, LDL, and non-HDL cholesterol were observed primarily after more than 10% weight reduction [36]. Weight loss plateaus — periods of several weeks with little or no scale movement — are widely reported by patients (see the [tirzepatide side effects](/side-effects) page and the [Tirzepatide effects](/effects) page) and are consistent with the metabolic adaptation seen during sustained caloric restriction. They are described in the clinical literature as a normal part of the weight-loss arc, not treatment failure. ## Why am I not losing weight on tirzepatide? What the trials show The clinical trial data is a population average — the -20.9% mean at 72 weeks in SURMOUNT-1 encompasses a wide range of individual responses. Several factors documented in the literature are associated with attenuated response: **Dose.** The dose-response relationship is clear in the SURMOUNT-1 data: the 5 mg arm achieved -15.0% mean weight loss, the 10 mg arm -19.5%, and the 15 mg arm -20.9%. The titration schedule exists in the label to allow doses to be increased to tolerance [4]. **Time.** The plateau effect is real. SURMOUNT-3 (Wadden TA et al., Nat Med 2023) demonstrated meaningful additional weight loss even in participants who had already achieved at least 5% body weight reduction with intensive lifestyle intervention before starting tirzepatide — the drug still produced an additional -18.4% mean weight change from randomisation over 72 weeks [30]. The weight-loss curve in the trials typically shows faster early loss and a slower plateau phase at later weeks. **Discontinuation effect.** SURMOUNT-4 (Aronne LJ et al., JAMA 2024) is the most direct evidence for what happens if treatment stops. Participants who switched from tirzepatide to placebo regained weight, while those continuing on treatment kept losing. The mean weight regain after stopping was substantial and tracked with worsening cardiometabolic risk factors [14]. This frames the treatment in the clinical literature as a chronic rather than short-course therapy. The [Tirzepatide references](/references) page has the full citation record. --- Peer-reviewed trial findings on tirzepatide, walked through step by step — not a prescription, not a clinic, not a vendor.